"Prednisolone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
| Descriptor ID |
D011239
|
| MeSH Number(s) |
D04.210.500.745.432.769.795
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Prednisolone".
Below are MeSH descriptors whose meaning is more specific than "Prednisolone".
This graph shows the total number of publications written about "Prednisolone" by people in this website by year, and whether "Prednisolone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 2 | 3 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 4 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 6 | 6 |
| 2020 | 2 | 2 | 4 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
| 2024 | 2 | 0 | 2 |
| 2025 | 0 | 1 | 1 |
| 2026 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prednisolone" by people in Profiles.
-
Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial. Nat Commun. 2026 07 30; 17(1).
-
Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis. Blood Adv. 2026 Jul 14; 10(13):4776-4785.
-
Diaphragm-specific effects of L-citrulline in mdx mice highlight its potential as adjuvant of standard therapy in Duchenne muscular dystrophy. Br J Pharmacol. 2026 Jul; 183(13):3866-3884.
-
Corticosteroids in severe alcohol-associated hepatitis. Not so fast: A systematic review of randomized controlled trials. Hepatology. 2025 Nov 01; 82(5):1241-1255.
-
A Case of IgG4-Related Disease Manifesting as Extensive Abdominal Periarteritis and Membranous Nephropathy, Successfully Controlled with Low-Dose Steroid Therapy without Relapse or Complications. Nephron. 2025; 149(4):213-221.
-
Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inFLAMmatory heart disease using cardiovascular magnetic resonance Endpoints. J Cardiovasc Magn Reson. 2025; 27(1):101121.
-
Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2023 Apr; 117(4):578-589.
-
2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021 11; 8(1).
-
Diagnostic and Therapeutic Challenge. Retina. 2021 Jul 01; 41(7):1570-1576.
-
Immune thrombocytopenia following multisystem inflammatory syndrome in children (MIS-C) - a case series. Pediatr Hematol Oncol. 2021 Oct; 38(7):663-668.